Albireo Pharma, Inc. (NASDAQ:ALBO) saw unusually-strong trading volume on Thursday . Approximately 38,779 shares changed hands during trading, a decline of 62% from the previous session’s volume of 102,429 shares.The stock last traded at $34.41 and had previously closed at $36.00.

A number of equities analysts recently commented on ALBO shares. BidaskClub upgraded Albireo Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. Wedbush restated a “buy” rating on shares of Albireo Pharma in a report on Friday, January 19th. Zacks Investment Research upgraded Albireo Pharma from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a report on Monday, January 8th. Cowen restated a “buy” rating on shares of Albireo Pharma in a report on Friday, November 17th. Finally, Roth Capital started coverage on Albireo Pharma in a report on Wednesday, November 15th. They set a “buy” rating and a $92.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $58.25.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.12. analysts predict that Albireo Pharma, Inc. will post -3.42 EPS for the current year.

In other Albireo Pharma news, major shareholder Plc Astrazeneca sold 500,000 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total value of $3,444,000.00. The disclosure for this sale can be found here. 22.30% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in Albireo Pharma by 282.1% in the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 4,688 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Albireo Pharma during the 4th quarter worth about $216,000. Finally, Artal Group S.A. acquired a new stake in shares of Albireo Pharma during the 4th quarter worth about $7,680,000. 23.89% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Albireo Pharma (ALBO) Sees Unusually-High Trading Volume” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2018/02/10/albireo-pharma-albo-sees-unusually-high-trading-volume.html.

About Albireo Pharma

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.